6. Gems picture of the month

World’s first ultra rapid-acting insulin - FiAsp

Insulin aspart, with the global trade name NovoRapid, has been on the market worldwide for more than a decade for the treatment of diabetes mellitus.Fiasp is insulin aspart in a new formulation.Compared to NovoRapid, Fiasp contains two additional excipients: nicotinamide (also known as niacinamide or vitamin B3) and L-arginine hydrochloride (an amino acid). The addition of nicotinamide result in a faster initial absorption of insulin aspart following subcutaneous injection. The addition of L-arginine hydrochloride support stabilisation of the Fiasp formulation.

Fiasp is the world’s first ultra-fast acting insulin with twice as fast onset of appearance and two-fold greater early insulin exposure compared to insulin aspart. It has 74% greater insulin action within first 30 mins. US FDA approved fast-acting insulin aspart for the treatment of adults with diabetes in September 2017 and the formulation is available in India since March 2019.

This newsletter is published for free distribution through the Internet for doctors, patients and public for promoting healthy lifestyles.
For enquiries info@jothydev.net.
Please visit: jothydev.net | research.jothydev.com | diabscreenkerala.net | jothydev.com/newsletter